Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
February 17 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that the
Company’s management team will participate in a fireside chat on
Wednesday, February 24, 2021 at 10:00 a.m. ET at the SVB Leerink
10th Annual Global Healthcare Conference.
A live webcast of the presentation will be
available on the Investors & Media section of Mersana’s website
at www.mersana.com. An archived replay will be available for
approximately 90-days following the presentation.
About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (XMT-1536, UpRi), is in the expansion portion of a Phase
1 proof-of-concept clinical study in patients with ovarian cancer
and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product
candidate targeting NaPi2b-expressing tumors, was created using
Mersana’s customizable and homogeneous Dolasynthen platform and is
in the dose escalation portion of a Phase 1 proof-of-concept
clinical study. The Company’s early-stage programs include
XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a
STING-agonist ADC developed using the Company’s Immunosynthen
platform. In addition, multiple partners are using Mersana’s
Dolaflexin platform to advance their ADC pipelines.
Contact:Investor & Media
ContactSarah Carmody617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024